Imperial College London

Positive topline results from Phase III long-term study OASIS 3 support submissions for marketing authorization for Bayer’s elinzanetant

Retrieved on: 
火曜日, 3月 19, 2024
Health, Fitness & Nutrition, Clinical Trials, Research, Pharmaceutical, Science, International Menopause Society, VMS, Menopause, OASIS, Executive Committee, Imperial College London, Woman, Hot, Safety, Elinzanetant, Phase, Marketing, Pharmaceutical industry

Bayer today announced positive topline results of the Phase III study OASIS 3 evaluating the efficacy and long-term safety of the investigational compound elinzanetant versus placebo.

Key Points: 
  • Bayer today announced positive topline results of the Phase III study OASIS 3 evaluating the efficacy and long-term safety of the investigational compound elinzanetant versus placebo.
  • The long-term safety profile observed over 52 weeks in the OASIS 3 study is overall consistent with previously conducted studies and published data1,2 on elinzanetant.
  • “OASIS 3 was designed to address the important question of the long-term profile of elinzanetant.
  • “These results, coupled with the recent announcement of topline data for OASIS 1 and OASIS 2, strengthen our confidence in the proposed efficacy and safety of elinzanetant as a potential novel non-hormonal solution for women experiencing menopause-related symptoms.”
    OASIS 3 (NCT05030584) is the third Phase III study in the OASIS clinical development program with positive topline results.

SHL Telemedicine Receives Buy Rating with $11.00 Price Target

Retrieved on: 
木曜日, 3月 14, 2024
Software, Telemedicine, Virtual Medicine, Finance, Health, Health Technology, Professional Services, Technology, Apps, Applications, Research, The Wall Street Journal, Growth, Clinical professor, Mayo Clinic, Telehealth, SHL, Imperial College London, Clinical trial, Wells Fargo, FINRA, Pharmaceutical industry

SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is pleased to announce that Litchfield Hills Research, a leading equity research firm has initiated coverage of with a 'Buy' rating and an $11.00 price target.

Key Points: 
  • SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is pleased to announce that Litchfield Hills Research, a leading equity research firm has initiated coverage of with a 'Buy' rating and an $11.00 price target.
  • This price target represents a significant premium over the company's current share price, highlighting the firm's confidence in SHL's growth trajectory and market position.
  • The equity research report emphasizes SHL Telemedicine's innovative approach and expanding market opportunities, noting that "SHLT is a pure-play in the rapidly expanding $115B telemedicine market.
  • The $11.00 price target is based on a comprehensive analysis of the company's financial health, growth prospects, and the expanding market for telemedicine services.

Enhanced Games respond to White House "Deep Concern"; Invite Collaboration with IOC

Retrieved on: 
月曜日, 3月 18, 2024
Olympic Games, Conference, Prevalence, Sport, Frailty, Science, Professor, Partnership, White, Journal, Research, Tobacco, MD, Athlete, Parliament, Imperial College London, IOC, Cannabis, Enhanced, Sports medicine, Lancet, WADA, Entertainment

The Enhanced Games respond to "deep concern" comments from the White House with a pledge to unwavering commitment to fairness in sports competition, supported by rigorous science.

Key Points: 
  • The Enhanced Games respond to "deep concern" comments from the White House with a pledge to unwavering commitment to fairness in sports competition, supported by rigorous science.
  • In a bid to foster informed discourse, the Enhanced Games extend an invitation to the IOC and the White House to engage in collaborative dialogue, just as the British Parliament did by convening the First Conference on Human Enhancement in collaboration with the Enhanced Games last month.
  • Only with a formal partnership between the IOC and Enhanced Games, can Olympics drug testing finally be effective and ensure the integrity of their games."
  • Journalists are invited to join one of two virtual press conferences with Dr Aron D'Souza, President of the Enhanced Games:

BioInnovation Institute welcomes innovative smartRNA project to Bio Studio program

Retrieved on: 
木曜日, 3月 14, 2024
Lykke, Epilepsy, EUR, KU Leuven, European Molecular Biology Laboratory, Haploinsufficiency, Genetics, Patient, Research, RNA, University of Washington, University, Messenger, Cancer, Laboratory, BII, Imperial College London, Student, EMBL, Monogenic, Aarhus University, University of Copenhagen, Intellectual property, Therapy, Molecular biology, DSM-IV codes, Disorder, Vaccine

Thus, the aim of the smartRNA project in BII's Bio Studio program is to leverage this proprietary technology to develop treatments for currently untreatable disorders caused by haploinsufficiency or other monogenic diseases caused by reduced protein activity.

Key Points: 
  • Thus, the aim of the smartRNA project in BII's Bio Studio program is to leverage this proprietary technology to develop treatments for currently untreatable disorders caused by haploinsufficiency or other monogenic diseases caused by reduced protein activity.
  • During the 3-year BII Bio Studio program, the objective of smartRNA is to deliver an in vitro proof-of-concept, a pseudo in vivo proof-of-principle, and in vitro benchmarking against established technologies.
  • Anja Mølhart Høg, Entrepreneur-in-Residence heading up the smartRNA project, added: "We are excited to welcome the smartRNA project to BII's Bio Studio program.
  • The Bio Studio program is a recently established BII program with the ambition to build and run a leading life science company creation facility in Europe.

BioInnovation Institute welcomes innovative smartRNA project to Bio Studio program

Retrieved on: 
木曜日, 3月 14, 2024
Lykke, Epilepsy, EUR, KU Leuven, European Molecular Biology Laboratory, Haploinsufficiency, Genetics, Patient, Research, RNA, University of Washington, University, Messenger, Cancer, Laboratory, BII, Imperial College London, Student, EMBL, Monogenic, Aarhus University, University of Copenhagen, Intellectual property, Therapy, Molecular biology, DSM-IV codes, Disorder, Vaccine

Thus, the aim of the smartRNA project in BII's Bio Studio program is to leverage this proprietary technology to develop treatments for currently untreatable disorders caused by haploinsufficiency or other monogenic diseases caused by reduced protein activity.

Key Points: 
  • Thus, the aim of the smartRNA project in BII's Bio Studio program is to leverage this proprietary technology to develop treatments for currently untreatable disorders caused by haploinsufficiency or other monogenic diseases caused by reduced protein activity.
  • During the 3-year BII Bio Studio program, the objective of smartRNA is to deliver an in vitro proof-of-concept, a pseudo in vivo proof-of-principle, and in vitro benchmarking against established technologies.
  • Anja Mølhart Høg, Entrepreneur-in-Residence heading up the smartRNA project, added: "We are excited to welcome the smartRNA project to BII's Bio Studio program.
  • The Bio Studio program is a recently established BII program with the ambition to build and run a leading life science company creation facility in Europe.

Beckley Waves Celebrates a Year of Milestones, Including $3.3 Million in New Funding, 200 Retreat Participants, the Inaugural Cohort of Therapist Training, and the Acquisition of Ketamine Therapy Provider Nue Life

Retrieved on: 
火曜日, 3月 5, 2024
Psilocybin, Mental health, Woman, ICL, Research, Beckley Foundation, Suicide, Spirituality, Curriculum, Entrepreneurship, MDMA, BIPOC, Ketamine, Veteran, PAT, Imperial College London, Partnership

Through its portfolio of operating companies, Beckley Waves has also expanded programs for practitioner training and psilocybin retreats, accelerating the company’s growth.

Key Points: 
  • Through its portfolio of operating companies, Beckley Waves has also expanded programs for practitioner training and psilocybin retreats, accelerating the company’s growth.
  • In September, the company also acquired at-home ketamine therapy provider Nue Life and will continue Nue Life’s work to provide safe and scalable access to ketamine-assisted therapy in underserved areas across multiple US states.
  • In 2024, Beckley Retreats will offer dedicated retreats in Jamaica and the Netherlands that will be exclusively for women, veterans, and the BIPOC community.
  • "With our ongoing momentum, we will keep the flywheel spinning and continue to allow the Beckley Waves Ecosystem to play a catalytic role in our shared path to widespread access."

CEO Club Hosts Successful AI Conference Featuring Prominent Industry Leaders

Retrieved on: 
金曜日, 3月 8, 2024
Corporate governance, ICU, Artificial intelligence, Club, Future, Help, Keynote, Partnership, Public sector, Public, Imperial College London, Medical device

LONDON, March 8, 2024 /PRNewswire/ -- The CEO Club proudly hosted an engaging AI conference on February 27th, bringing together esteemed experts and industry leaders to delve into the present and future of artificial intelligence (AI).

Key Points: 
  • LONDON, March 8, 2024 /PRNewswire/ -- The CEO Club proudly hosted an engaging AI conference on February 27th, bringing together esteemed experts and industry leaders to delve into the present and future of artificial intelligence (AI).
  • The conference commenced with a riveting Keynote Address titled "AI: Our Present and What the Future Promises?"
  • Guests in attendance included CEO Club members, business representatives, founders, and diplomats, all of whom actively participated in the enriching dialogue and networking opportunities provided by the conference.
  • The CEO Club extends its gratitude to all participants, speakers, and members for their contributions to the success of the AI conference.

ATLAS OCEAN VOYAGES INTRODUCES NEW CULTURAL EXPEDITION PROGRAMMING FOR 2024

Retrieved on: 
木曜日, 3月 7, 2024
Museum, Social work, Royal Horticultural Society, Architecture, Doctor of Philosophy, Royal, Culture, Medical microbiology, Scott Polar Research Institute, University, RSPB, Religious broadcasting, Victoria and Albert Museum, Fossil, Local government, Atlas, British Museum, Fellow, Plant, University of Leicester, MBA, Radio, Gardening, BBC, Economics, Disabled parking permit, Environmental science, Education, Pepperdine University, FPV, Pritikin diet, Life, American Red Cross, Physics, Exploration, Research, Collection, Politics, Royal Society, University of Cambridge, Radio 4, Arawak, Emeritus, Imperial College London, Carib, WSI, Geological Society of London, UC, Emmanuel College, RHS, Tourism

FORT LAUDERDALE, Fla., March 7, 2024 /PRNewswire/ -- Atlas Ocean Voyages announces a collection of expert-led workshops and onboard lecturers as part of the 2024 Cultural Expeditions season. An addition to the company's year-round expeditions that include Polar and Epicurean Expeditions, these new programs enhance appreciation for a variety of captivating regions and local cultures.

Key Points: 
  • FORT LAUDERDALE, Fla., March 7, 2024 /PRNewswire/ -- Atlas Ocean Voyages announces a collection of expert-led workshops and onboard lecturers as part of the 2024 Cultural Expeditions season.
  • Atlas Ocean Voyages Cultural Expeditions include onboard and onshore programming focused on drone and photo workshops, cooking culture, and destination experts.
  • Below is an overview for 2024:
    Guests will embark on an exhilarating journey exclusively with Atlas Ocean Voyages Cultural Expeditions' new Atlas Focus Lab: Drone & Photo Workshops.
  • Combining an intimate and luxurious environment with genuine hospitality, Atlas Ocean Voyages ensures that each journey is a once-in-a-lifetime expedition.

Manulife announces additions to its Board of Directors

Retrieved on: 
火曜日, 3月 5, 2024
Market, Bank, Eastspring Investments, Prudential plc, AIG, Commerce, University, Partnership, Society of Actuaries, Espresso, Towers Perrin, Boston Consulting Group, MBA, RGA, Greater China, PhD in management, Scotiabank, Chairperson, Kanak people, Imperial College London, Saint Mary's University, Life, Chemical engineering, Master of Letters, Actuarial science, Compensated emancipation, JD, University of Oxford, Master of Science, Investment, Insurance, Corporate governance, Harvard University, Reinsurance Group of America, Senior advisor, Harvard Law School, Queen's University, Audit committee, Committee, American International Group, Management

He holds a Bachelor of Commerce from Saint Mary's University and a Ph.D. in Management from Queen's University.

Key Points: 
  • He holds a Bachelor of Commerce from Saint Mary's University and a Ph.D. in Management from Queen's University.
  • Mr. Kanak is a former senior executive with deep insurance experience in Asia.
  • He served in senior executive positions at American International Group (AIG) for over 14 years before joining Prudential.
  • "Mike, Don, Anna and John bring skills and experience critical to supporting the Board of Directors' effective oversight of Manulife given its growth ambitions and strategic priorities," said Don Lindsay, Chair of the Board, Manulife.

Hamdi Ulukaya Joins the Aurora Prize Selection Committee

Retrieved on: 
水曜日, 2月 28, 2024
Laureate, Refugee, Chobani, Person, Selection Committee, Entrepreneurship, Risk, UCLA, Imperial College London, Partnership, Pharmaceutical industry

BOSTON, Feb. 28, 2024 /PRNewswire/ -- The Aurora Humanitarian Initiative announced today that Hamdi Ulukaya, Founder and CEO of Chobani and Founder of the Tent Partnership for Refugees, has joined the Selection Committee for the Aurora Prize for Awakening Humanity, a $1 million global humanitarian award. Mr. Ulukaya joins distinguished members of the Aurora Prize Selection Committee to choose the Aurora Prize Humanitarians and Laureate.

Key Points: 
  • BOSTON, Feb. 28, 2024 /PRNewswire/ -- The Aurora Humanitarian Initiative announced today that Hamdi Ulukaya, Founder and CEO of Chobani and Founder of the Tent Partnership for Refugees, has joined the Selection Committee for the Aurora Prize for Awakening Humanity, a $1 million global humanitarian award.
  • Mr. Ulukaya joins distinguished members of the Aurora Prize Selection Committee to choose the Aurora Prize Humanitarians and Laureate.
  • "We are grateful for Hamdi's outstanding efforts and look forward to his active participation as a member of the Aurora Prize Selection Committee."
  • "The Aurora Prize will benefit greatly from Hamdi's expertise and perspective that will further enhance the ability for the Aurora Prize to continue to strengthen its impact on those most in need."